History

Affectis Pharmaceuticals started operations in January 2004 as a spin-off from the Max Planck Institute of Psychiatry. The company’s founders include Florian Holsboer, a key opinion leader in psychiatry, Wolfgang Wurst, an expert in mouse genetics, and Herbert Stadler, a serial biotech entrepreneur.

Affectis' unique capabilities in drug discovery and medicinal chemistry allow the company to develop drugs with innovative mechanisms of action based on pioneering findings in the field of P2X7 receptors, neurodegeneration and neuroinflammation. Affectis develops proprietary drug candidates from discovery to clinical stage and will partner or license its programs at late development stage. Affectis has successfully partnered several of its programs.

The company is located in Martinsried near Munich, Germany.